An international research team reveals new molecular mechanisms associated with pathogenic mutations in the protein transthyretin that cause transthyretin amyloidosis (ATTR), a group of fatal progressive diseases. The results, obtained thanks to a new methodological approach, open the door to the development of drugs with higher therapeutic potential, designed specifically for the variants of the protein associated with the disease.
